TNYA is trading 5% up today at $0.75 in pre-market, recovering modestly after recent weakness in the sub-$1 range.
- The move appears driven by light pre-market trading and normal volatility in a low-priced biotech rather than a defined catalyst.
- There have been no fresh company-specific headlines, earnings reports, FDA updates, or deal news since prior conference-participation announcements.